| dc.contributor.author | Dube, Admire | |
| dc.date.accessioned | 2020-07-14T14:05:05Z | |
| dc.date.available | 2020-07-14T14:05:05Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Dube, A. Nanomedicines for Infectious Diseases. Pharm Res 36, 63 (2019). https://doi.org/10.1007/s11095-019-2603-x | en_US |
| dc.identifier.uri | https://doi.org/10.1007/s11095-019-2603-x | |
| dc.identifier.uri | http://hdl.handle.net/10566/5239 | |
| dc.description.abstract | Infectious diseases continue to pose a significant threat to global health. Over 200 infectious diseases are currently known to man. Fortunately, only a handful are responsible for significant morbidity and mortality. HIV/AIDS, tuberculosis (TB) and malaria top the list of deadly infectious diseases, and worldwide, these three diseases combined, are responsible for over 3 million deaths every year (1). Outbreaks of infectious diseases are also not uncommon and examples in recent history include the Ebola virus, Zika virus and Avian flu outbreaks which originated in West Africa, South America and Asia, respectively, before spreading to other parts of the world (2–4). This further emphasizes the global concern over infectious diseases. | en_US |
| dc.description.sponsorship | The author acknowledges funding from the Fogarty International Center of the National Institutes of Health under Award Number K43TW010371. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Springer Nature | en_US |
| dc.subject | Nanomedicine | en_US |
| dc.subject | Infectious diseases | en_US |
| dc.subject | Tuberculosis | en_US |
| dc.title | Nanomedicines for infectious diseases | en_US |
| dc.type | Article | en_US |
